Kerala has passed its COVID-19 peak and in the next 2 weeks, a decline in cases should start in the state, said Dr Sanjay Rai, AIIMS Professor on Tuesday.
Rai told ANI, "Earlier sero survey in Kerala suggest that most population was susceptible but latest sero survey shows that 46 per cent had antibodies due to vaccine or by infection. The measures are taken by the state only slows down the spread. By looking at the data of the virus spread in last 2-3 months, Kerala has passed its peak and in the next 2 weeks, a decline in cases should start. Just like North-East, Kerala should also start witness drop in COVID cases by the start of October as per the epidemiological picture."
AIIMS will be starting Phase 2/3 trials of Hyderabad-based COVID-19 vaccine manufacturer Bharat Biotech's nasal vaccine soon and the application has been put to seek the mandatory permission of the Ethics Committee.
"It is very early to say but we believe that future is promising for Nasal Vaccine as it can provide mucosal immunity, then infection prevention is possible. Most of the vaccines are not able to stop the infection, they only reduce the severity. The Nasal vaccine has gone for ethical approval and after the approval, we will start the trial," said Dr Rai, who is also Bharat Biotech's nasal vaccine clinical trial's principal investigator.
The adenoviral intranasal vaccine BBV154 is the first of its kind COVID-19 vaccine to undergo human trials in India.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)